Company intelligence / Profile preview

Akston Biosciences Corporation

Beverly, Massachusetts, United Statesakstonbio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has developed once-weekly insulin therapies for dogs and cats that are being commercialized with Dechra Pharmaceuticals. They previously worked on a COVID-19 vaccine (AKS-452) that showed stability at room temperature for at least six months and completed Phase I/II clinical trials.

Therapeutic areas: OncologyEndocrinologyNeurologyInfectious Diseases
Modalities: Protein therapeuticsFc-fusion proteinsbiologics
Industry: Veterinary

Drug pipeline

2 assets

AKS-321d

Phase 2

Indications: Diabetes

1 more asset in the full pipeline.

Partnerships

Dechra Pharmaceuticals PLC

Beyond the preview

Go deeper on Akston Biosciences Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akston Biosciences Corporation.